Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

USAMA GERGIS

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1548450984
CMS profile
343054
Location
ALLENTOWN, PA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$184,338.31

162 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

By paying entity

PY2022 · entire year · sorted by reported total

Paying entityAmountRecords
Kite Pharma, Inc. $65,683.44 47
JAZZ PHARMACEUTICALS INC. $62,393.45 54
Incyte Corporation $37,445.07 43
Astellas Pharma US Inc $12,618.43 12
Novartis Pharmaceuticals Corporation $4,997.92 3
National Marrow Donor Program $1,200.00 3

Page 2 of 4; records 51–100 of 162 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

USAMA GERGIS

NPI 1548450984 · CMS profile ID 343054

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

ALLENTOWN, PA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 4; records 51–100 of 162 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1548450984?year=2022&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
USAMA GERGIS, NPI 1548450984, CMS profile ID 343054. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 162 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1548450984?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). USAMA GERGIS, NPI 1548450984, CMS profile ID 343054. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 162 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1548450984?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
USAMA GERGIS, NPI 1548450984, CMS profile ID 343054, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 4; records 51–100 of 162 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1548450984?year=2022&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

162 matching records · $184,338.31 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 162 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 162.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Kite Pharma, Inc. $49.0209/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920069685 CMS
Kite Pharma, Inc. $49.0209/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920069687 CMS
Kite Pharma, Inc. $215.4609/16/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920069675 CMS
Kite Pharma, Inc. $622.2009/16/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920069679 CMS
Kite Pharma, Inc. $87.7709/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920065453 CMS
Kite Pharma, Inc. $83.6109/14/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920065459 CMS
Kite Pharma, Inc. $783.8509/13/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920065443 CMS
JAZZ PHARMACEUTICALS INC. $16.3209/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 951400611 CMS
JAZZ PHARMACEUTICALS INC. $49.8309/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 951400613 CMS
JAZZ PHARMACEUTICALS INC. $52.3409/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 951400615 CMS
JAZZ PHARMACEUTICALS INC. $110.6609/07/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 951400617 CMS
JAZZ PHARMACEUTICALS INC. $7,040.0009/06/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 951400607 CMS
Kite Pharma, Inc. $3,950.0008/26/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920065151 CMS
JAZZ PHARMACEUTICALS INC. $556.8708/24/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 951400623 CMS
JAZZ PHARMACEUTICALS INC. $238.2008/24/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 951400625 CMS
JAZZ PHARMACEUTICALS INC. $196.2008/24/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 951400627 CMS
Kite Pharma, Inc. $5,140.0008/22/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920065103 CMS
Kite Pharma, Inc. $150.0008/19/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920062769 CMS
JAZZ PHARMACEUTICALS INC. $159.8508/18/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 951400621 CMS
Kite Pharma, Inc. $1,375.5808/18/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920065101 CMS
Kite Pharma, Inc. $125.0008/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920065105 CMS
JAZZ PHARMACEUTICALS INC. $84.4408/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 951400609 CMS
JAZZ PHARMACEUTICALS INC. $125.0008/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 951400595 CMS
Kite Pharma, Inc. $5,140.0008/10/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920062767 CMS
Kite Pharma, Inc. $68.9908/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920062765 CMS
JAZZ PHARMACEUTICALS INC. $678.2008/06/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 951400619 CMS
Incyte Corporation $6,918.7507/08/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 943021567 CMS
Incyte Corporation $3,075.0007/08/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 943021587 CMS
Kite Pharma, Inc. $3,950.0007/01/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920064881 CMS
National Marrow Donor Program $400.0007/01/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 924685727 CMS
JAZZ PHARMACEUTICALS INC. $27.5206/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 951398763 CMS
JAZZ PHARMACEUTICALS INC. $107.1006/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 951398765 CMS
JAZZ PHARMACEUTICALS INC. $193.7106/22/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 951398767 CMS
Kite Pharma, Inc. $1,975.0006/21/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920064877 CMS
Novartis Pharmaceuticals Corporation $2,025.0006/17/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893692987 CMS
Kite Pharma, Inc. $3.4806/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920062637 CMS
Kite Pharma, Inc. $13.5606/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920062639 CMS
Kite Pharma, Inc. $25.3006/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920062641 CMS
Kite Pharma, Inc. $3.3006/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920062669 CMS
Kite Pharma, Inc. $6.9206/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920062671 CMS
Incyte Corporation $59.1706/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 943021563 CMS
Incyte Corporation $10.2806/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 943021565 CMS
Incyte Corporation $158.4606/11/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 943021569 CMS
Incyte Corporation $48.7206/11/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 943021577 CMS
Incyte Corporation $24.3206/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 943021579 CMS
Incyte Corporation $48.6506/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 943021581 CMS
Incyte Corporation $16.2206/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 943021583 CMS
Incyte Corporation $48.6506/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 943021585 CMS
Incyte Corporation $24.3206/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 943021593 CMS
Incyte Corporation $158.4606/11/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 943021595 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $269,551.45 288
PY2020 $93,995.48 69
PY2021 $98,708.68 81
PY2022 $184,338.31 162
PY2023 $167,471.51 180
PY2024 $125,261.77 109
PY2025 $224,093.94 192

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $147,770.93 22
PY2024 Principal investigator $433,220.95 42
PY2023 Principal investigator $646,190.52 33
PY2022 Principal investigator $120,042.05 24
PY2021 Principal investigator $164,370.45 2
PY2020 Principal investigator $336,221.14 3
PY2019 Principal investigator $272,053.58 7

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

22 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $14,766.00 11/14/2025 Non-covered Recipient Entity
Thomas Jefferson University
A Phase 3, Multicenter, Randomized, Open-label Study to Compare the Efficacy and Safety of bb2121 Versus Standard Regimens in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM) (KarMMa-3) No dispute reported 06/30/2026 1235992939
Principal investigator 1 Janssen Research & Development, LLC $541.00 11/07/2025 Non-covered Recipient Entity
THOMAS JEFFERSON UNIVERSITY
A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) followed by Ciltacabtagene Autoleucel, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA versus Bortezomib, Lenalidomide, and Dexamethasone (VRd) followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants with Newly Diagnosed Multiple Myeloma for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy No dispute reported 06/30/2026 1175340942
Principal investigator 1 Janssen Research & Development, LLC $5,294.00 10/23/2025 Non-covered Recipient Entity
THOMAS JEFFERSON UNIVERSITY
A Phase 2 Multicohort Open Label Study of JNJ68284528 a Chimeric Antigen Receptor T cell CART Therapy Directed Against BCMA in Subjects with Multiple Myeloma No dispute reported 06/30/2026 1175340854
Principal investigator 1 Janssen Research & Development, LLC $541.00 10/06/2025 Non-covered Recipient Entity
THOMAS JEFFERSON UNIVERSITY
A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) followed by Ciltacabtagene Autoleucel, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA versus Bortezomib, Lenalidomide, and Dexamethasone (VRd) followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants with Newly Diagnosed Multiple Myeloma for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy No dispute reported 06/30/2026 1175341076
Principal investigator 1 Janssen Research & Development, LLC $541.00 09/04/2025 Non-covered Recipient Entity
THOMAS JEFFERSON UNIVERSITY
A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) followed by Ciltacabtagene Autoleucel, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA versus Bortezomib, Lenalidomide, and Dexamethasone (VRd) No dispute reported 06/30/2026 1175340804
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,600.00 08/26/2025 Covered Recipient Teaching Hospital
THOMAS JEFFERSON UNIV. HOSPITAL
TAK-012-1501 No dispute reported 06/30/2026 1223269758
Principal investigator 1 National Marrow Donor Program $1,500.00 08/08/2025 Non-covered Recipient Entity
Thomas Jefferson University
A Multi-Center, Phase II Trial of HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide for Patients With Hematologic Malignancies No dispute reported 06/30/2026 1249326309
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $43,976.95 08/05/2025 Covered Recipient Teaching Hospital
THOMAS JEFFERSON UNIV. HOSPITAL
TAK-012-1501 No dispute reported 06/30/2026 1223269740
Principal investigator 1 Janssen Research & Development, LLC $7,467.00 07/28/2025 Non-covered Recipient Entity
THOMAS JEFFERSON UNIVERSITY
A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) followed by Ciltacabtagene Autoleucel, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA versus Bortezomib, Lenalidomide, and Dexamethasone (VRd) No dispute reported 06/30/2026 1175340987
Principal investigator 1 Novartis Pharmaceuticals Corporation $143.18 07/28/2025 Non-covered Recipient Entity
THOMAS JEFFERSON UNIVERSITY HOSPITAL
Long Term Follow Up of Patients Exposed to Lentiviral Based CD19 Directed CAR T Cell Therapy No dispute reported 06/30/2026 1190307897
Principal investigator 1 Celgene Corporation $3,223.05 05/28/2025 Non-covered Recipient Entity
Thomas Jefferson University
A Phase 3, Multicenter, Randomized, Open-label Study to Compare the Efficacy and Safety of bb2121 Versus Standard Regimens in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM) (KarMMa-3) No dispute reported 06/30/2026 1222304587
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,694.00 05/13/2025 Non-covered Recipient Entity
THOMAS JEFFERSON UNIVERSITY
TAK-012-1501 No dispute reported 06/30/2026 1223279402
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,129.00 05/13/2025 Non-covered Recipient Entity
THOMAS JEFFERSON UNIVERSITY
TAK-012-1501 No dispute reported 06/30/2026 1223279404
Principal investigator 1 Janssen Research & Development, LLC $2,864.00 05/01/2025 Non-covered Recipient Entity
THOMAS JEFFERSON UNIVERSITY
A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) followed by Ciltacabtagene Autoleucel, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA versus Bortezomib, Lenalidomide, and Dexamethasone (VRd) No dispute reported 06/30/2026 1175340994
Principal investigator 1 Janssen Research & Development, LLC $24,510.00 04/07/2025 Non-covered Recipient Entity
THOMAS JEFFERSON UNIVERSITY
A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) followed by Ciltacabtagene Autoleucel, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA versus Bortezomib, Lenalidomide, and Dexamethasone (VRd) No dispute reported 06/30/2026 1175340889
Principal investigator 1 Janssen Research & Development, LLC $2,338.00 03/31/2025 Non-covered Recipient Entity
THOMAS JEFFERSON UNIVERSITY
A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) followed by Ciltacabtagene Autoleucel, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA versus Bortezomib, Lenalidomide, and Dexamethasone (VRd) No dispute reported 06/30/2026 1175341032
Principal investigator 1 Janssen Research & Development, LLC $5,370.00 03/03/2025 Non-covered Recipient Entity
THOMAS JEFFERSON UNIVERSITY
A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) followed by Ciltacabtagene Autoleucel, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA versus Bortezomib, Lenalidomide, and Dexamethasone (VRd) No dispute reported 06/30/2026 1175340764
Principal investigator 1 Janssen Research & Development, LLC $5,800.00 03/03/2025 Non-covered Recipient Entity
THOMAS JEFFERSON UNIVERSITY
A Phase 2 Multicohort Open Label Study of JNJ68284528 a Chimeric Antigen Receptor T cell CART Therapy Directed Against BCMA in Subjects with Multiple Myeloma No dispute reported 06/30/2026 1175341047
Principal investigator 1 Janssen Research & Development, LLC $2,514.00 02/10/2025 Non-covered Recipient Entity
THOMAS JEFFERSON UNIVERSITY
A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) followed by Ciltacabtagene Autoleucel, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA versus Bortezomib, Lenalidomide, and Dexamethasone (VRd) No dispute reported 06/30/2026 1175341017
Principal investigator 1 Novartis Pharmaceuticals Corporation $6,049.77 01/15/2025 Non-covered Recipient Entity
THOMAS JEFFERSON UNIVERSITY HOSPITAL
Phase II, Open Label, Study of PHE885, a B-cell Maturation Antigen (BCMA)-Directed CAR-T Cells in Adult Patients With Relapsed and Refractory Multiple Myeloma No dispute reported 06/30/2026 1190307899
Principal investigator 1 Novartis Pharmaceuticals Corporation $13,389.98 01/07/2025 Non-covered Recipient Entity
JEFFERSON MEDICAL COLLEGE RESIDENCY
Phase II, Open Label, Study of PHE885, a B-cell Maturation Antigen (BCMA)-Directed CAR-T Cells in Adult Patients With Relapsed and Refractory Multiple Myeloma No dispute reported 06/30/2026 1190305669
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $519.00 01/03/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
RELAPSED OR REFRACTORY (R/R) B-CELL NON-HODGKIN LYMPHOMA (NHL) No dispute reported 06/30/2026 1223273497